Allergopharma

Executive Summary

Allergopharma, a German biotechnology company founded in 1967 and now part of the Dermapharm Group, specializes in the research, development, and commercialization of allergen immunotherapy (AIT) products for IgE-mediated allergic diseases. With over 50 years of experience, the company offers high-quality, 'Made in Germany' diagnostic and therapeutic solutions that aim to provide long-term relief from allergy symptoms and improve patients' quality of life. Allergopharma's AIT products, including subcutaneous and sublingual formulations, target common allergens such as pollen, house dust mites, and insect venoms. The company benefits from Dermapharm's strong distribution network and manufacturing capabilities, ensuring a stable supply of products across Europe and select international markets. Its focus on causal treatment and sustained tolerization distinguishes it from symptomatic allergy therapies, positioning Allergopharma as a key player in the growing allergy immunotherapy market. Looking ahead, Allergopharma is poised for growth driven by expansion of its product portfolio and geographic reach. The company is advancing late-stage clinical trials for new allergy immunotherapy tablets to address unmet needs in pediatric and polysensitized patients. Additionally, it is exploring regulatory approvals in emerging markets to diversify revenue streams. With increasing global prevalence of allergic diseases and rising demand for disease-modifying therapies, Allergopharma's robust pipeline and established manufacturing expertise support a positive outlook. The company remains a steady performer within Dermapharm, with potential catalysts including new product launches, positive clinical data, and strategic partnerships that could enhance its market position.

Upcoming Catalysts (preview)

• Q3 2026EU Approval for New House Dust Mite Allergy Tablet70% success
• Q4 2026Expansion into Asian Markets via Licensing Deal60% success